Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
JN.1.64.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XDP.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
KR.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
KZ.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
KS.1.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.1.19NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HN.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JN.1.47NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HR.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HP.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GW.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GS.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XCF.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.34NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HY.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JC.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.105NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.9.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GM.3.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FT.3.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JD.1.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GJ.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HT.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.20NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JH.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
CK.1.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.34.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EG.2.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
JK.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HL.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XCDNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.44.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EG.2.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.37NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.45.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FP.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.102NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FK.1.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26650.4US
GN.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.35.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GE.1.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HE.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.33NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FY.4.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.99NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HW.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.4.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FE.1.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
HA.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.16.14NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used